Skip to content
Future Royal Pro

{‘She lacks zero experience’: this US medical establishment girds for Dr. Høeg's role at the Food and Drug Administration.

While the United States undertakes unprecedented adjustments to its immunization recommendations, a particular individual appears in a surprising turn: Tracy Beth Høeg, a US-based sports physician and public health researcher who initially gained attention by casting doubt on Covid vaccinations during the pandemic and has focused upon possible fatalities after COVID-19 vaccination in her short time at the Food and Drug Administration.

Planned Changes to Childhood Immunization Schedule

Public health authorities had intended to reveal sweeping revisions to the pediatric immunization program in December, bringing the US with the Danish immunization schedule, sources say – a significant shift that would put the US out of alignment with a large portion of the world with insufficient data for improved outcomes. This reveal has been postponed until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to address the audience at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth appointee to run the division this calendar year.

A Shift at the Agency

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a greater focus upon reevaluating previously authorized vaccines at the FDA.

The new acting director has often pushed for ending specific pediatric shot schedules in the US to become more similar to Denmark, a society with universal health coverage and a number of inhabitants about the population of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – usually the purview of Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Expertise

Dr. Høeg has little discernible background in medication creation, regulation or leadership, which has been standard for previous heads of the biologics center. She has served at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in managing a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past directors of CBER would “understand legal statutes and the science of medication creation”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that former directors who ran CBER have had.”

The drug center has an vast workload at the FDA, she pointed out.

“The public just pays attention on the innovative therapies, but the generic drug division approves numerous generic medications. There’s a biologic copycat branch, over-the-counter program and so forth, and each of these must be managed,” Dr. Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a major administrative element to the role, which manages over 5,000 staff members. “It’s a huge management job, if you execute it properly,” Woodcock added.

Agency Reaction and Controversial Initiatives

In response to concerns about Høeg’s fitness for the role and whether this assignment signifies more teamwork among FDA leaders on immunizations, a representative stated that the “inquiries are based on inaccurate assumptions”.

“Her resume is consistent with the responsibilities of her position,” the spokesperson said, citing the time Høeg spent advising the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s controversial expedited review system, a disputed rapid therapy clearance system that reportedly concerned her former heads. “How are these drugs being selected for this fast-track system? Who makes the decisions?” Dr. Howard said. “There is a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he said, “the agency appears to be shifting towards more relaxed oversight of all drugs, except for vaccines.”

Documented History on Vaccines

Concerning vaccines, Høeg has a more documented, if problematic, history, some experts said. She published a study using unverified public submissions to determine the frequency of heart inflammation following Covid vaccination. She counseled the Florida top health official Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccines are riskier than they are.

Among her “desired changes” for the new government included revising guidelines for novel immunizations and halting “non-essential” immunizations, she remarked post-election on a podcast. At the FDA, Dr. Høeg has according to sources suggested preventing young men from getting Covid vaccinations.

“She is an thorough dogmatist who begins with her preconceived notions and works backwards to accommodate the science in a very disingenuous, fraudulent way,” Howard said.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|

By

Richard Hoffman

A tech strategist with over a decade of experience in digital innovation and AI-driven solutions.

Future Royal Pro

Type to search articles.